Piramal Pharma Ltd's Q4FY25 Quarter Results
- 15 May 2025
Result Summary
- Piramal Pharma Ltd reported a 16.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.9%.
- Its expenses for the quarter were up by 7.7% QoQ and 11.0% YoY.
- The net profit increased 2651.9% QoQ and increased 102.1% YoY.
- The earnings per share (EPS) of Piramal Pharma Ltd stood at 0.8 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2578.74 | 2216.35 | 2188.08 | 16.4% | 17.9% |
Total Expenses | 2332.78 | 2166.60 | 2100.97 | 7.7% | 11.0% |
Profit Before Tax | 215.44 | 49.75 | 87.11 | 333.0% | 147.3% |
Tax | 126.21 | 63.12 | 44.78 | 100.0% | 181.8% |
Profit After Tax | 101.27 | 3.68 | 50.11 | 2651.9% | 102.1% |
Earnings Per Share | 0.80 | 0.00 | 0.40 | - | 100.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Piramal Pharma Ltd operates in the pharmaceutical industry, focusing on providing a range of pharmaceutical products and services. The company engages in the manufacturing and distribution of a wide array of pharmaceutical products, including but not limited to drugs in the areas of critical care, consumer products, and contract development and manufacturing. As of the latest updates I have access to, Piramal Pharma Ltd has been involved in expanding its product line and enhancing its market presence through strategic partnerships and acquisitions. However, any recent major developments beyond this timeframe are not available.
Revenue
For the quarter ending in Q4FY25, Piramal Pharma Ltd reported a total income of ₹2578.74 crores. This represents a significant increase of 16.4% compared to the previous quarter (Q3FY25), where the total income was ₹2216.35 crores. Furthermore, on a year-over-year basis, total income rose by 17.9% from Q4FY24, where the income was ₹2188.08 crores. This upward trend in revenue indicates a robust performance during this period, reflecting the company's ability to generate higher sales or income from its operations.
Profitability
Piramal Pharma Ltd's profitability metrics show substantial growth during Q4FY25. The company reported a Profit Before Tax (PBT) of ₹215.44 crores, marking an increase of 333.0% quarter-over-quarter from ₹49.75 crores in Q3FY25. Year-over-year, PBT increased by 147.3% from ₹87.11 crores in Q4FY24. The Profit After Tax (PAT) for Q4FY25 was ₹101.27 crores, a remarkable improvement of 2651.9% from ₹3.68 crores in the previous quarter and 102.1% from ₹50.11 crores in the same quarter last year. The Earnings Per Share (EPS) for this quarter was ₹0.80, which doubled from ₹0.40 in Q4FY24.
Operating Metrics
The total expenses for Q4FY25 amounted to ₹2332.78 crores, reflecting a quarter-over-quarter increase of 7.7% from the ₹2166.60 crores recorded in Q3FY25. Year-over-year, total expenses increased by 11.0% from ₹2100.97 crores in Q4FY24. The tax expenses for the quarter were ₹126.21 crores, which doubled from ₹63.12 crores in the previous quarter and increased by 181.8% from ₹44.78 crores in Q4FY24. These figures show a consistent rise in both revenue and expenses, with a notable increase in tax liabilities, reflecting the company's growing profitability within the given timeframe.